MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Posted November 7, 2023 by DSouza

All key secondary endpoints were met for the 60mg and 120mg doses with induction. The key secondary endpoint Psoriasis Area and Severity Index (PASI) 90 was met for all doses

 
- First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile
- Primary endpoint ACR50 met with up to 47% (p
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Knowledge Bylanes
Business Address Press Centre
Karachi Pakistan
Country Pakistan
Categories Miscellaneous
Tags sonelokimab
Last Updated November 7, 2023
Unlock Peaceful Productivity and Sleep with Wayne Dreadski's "LoFi Oasis"
MAXIMANCE 2030 LTD Backs BlueGrace Energy Bolivia in Groundbreaking Project, Fulfilling Over 90% of UN Sustainable Development
Disposable Bedsheets Market by Covid-19 Impact Analysis, Size, Regional Growth, Major Key Players, Technology and Industry Trends Till 2028
Aerostructures Market Analysis: A Comprehensive Overview
Your Key to a Stress-Free Move With The Best Office and Residential Moving Services in Bellevue, Washington, at Team Worx Moving
Safely Submerged in The Water Are Submersible Well Pumps
Union Locksmith Emerges as the Go-To 24-Hour Locksmith Service Provider in OKC
Enterprise Streaming Media Market Key Opportunities And Strategies 2023-2032
Achieve Your Life Goals with Career and Life Coach
Lotus Book Offers Winning Opportunities In Cricket Betting To Gamers
©2010-2023 PRFREE.ORG